The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas.
The prognosis for children with bone and soft tissue sarcomas has significantly improved since the advent of effective multiagent chemotherapy, aggressive surgery for local disease and more precise delivery of radiotherapy doses. However, in a small proportion of patients that present with high-risk disease, long-term outcome has not substantially increased, with disease-free survival rates still in the order of 20-30%. It is therefore clear that novel therapies are needed for children with these tumors. Based on the highly chemosensitive nature of the majority of pediatric sarcomas, several small studies have been conducted to investigate the potential role of high-dose chemotherapy followed by hematopoietic stem cell reconstitution. This review will provide an overview of the current literature concerning the use of high-dose therapy with stem cell transplantation for the three main pediatric sarcomas--Ewing sarcoma, rhabdomyosarcoma and osteosarcoma.
Ek
Eugene T H
ET
Department of Orthopedics, St. Vincent's Hospital, Melbourne, Australia. eugene_ek@msn.com
Choong
Peter F M
PF
D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy*; D011379:Prognosis; D012307:Risk Factors; D012509:Sarcoma / Q000188:drug therapy*; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous